YD Bio Limited (YDES)
NASDAQ: YDES · Real-Time Price · USD
2.295
-0.069 (-2.92%)
At close: Aug 7, 2026, 4:00 PM EDT
2.290
-0.005 (-0.22%)
After-hours: Aug 7, 2026, 5:05 PM EDT
YD Bio Revenue
In the year 2024, YD Bio had annual revenue of $510.36K with 45.76% growth. YD Bio had revenue of $142.69K in the quarter ending December 31, 2024, with 95.63% growth.
Revenue (ttm)
$510.36K
Revenue Growth
+45.76%
P/S Ratio
316.22
Revenue / Employee
n/a
Employees
n/a
Market Cap
161.38M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 510.36K | 160.23K | 45.76% |
| Dec 31, 2023 | 350.13K | -13.99K | -3.84% |
| Dec 31, 2022 | 364.12K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
YDES News
- 10 days ago - YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada - GlobeNewsWire
- 15 days ago - YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services - GlobeNewsWire
- 5 weeks ago - YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations - GlobeNewsWire
- 3 months ago - YD Bio Limited Reports Full Year 2025 Financial Results - GlobeNewsWire
- 4 months ago - YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States - GlobeNewsWire
- 5 months ago - YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem - GlobeNewsWire
- 5 months ago - YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform - GlobeNewsWire
- 6 months ago - YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy - GlobeNewsWire